- Conditions
- PROSTATE CANCER
- Interventions
- Docetaxel and Prednisone, Radiation Therapy
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 6,946
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors
- Interventions
- XB371
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Rogers, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Imatinib mesylate
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Pharmacokinetics of ASKP1240, Pharmacodynamics of ASKP1240, Healthy Volunteers
- Interventions
- ASKP1240
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more
- Conditions
- Pain
- Interventions
- Oxycodone
- Drug
- Lead sponsor
- Pain Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Volunteers
- Interventions
- BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- M200 (Volociximab), Liposomal Doxorubicin
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- Anaheim, California • Redondo Beach, California • Sunrise, Florida + 11 more
- Conditions
- Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
- Interventions
- Azacitidine, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Nephrotic Syndrome in Children
- Interventions
- Corticosteroids
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Combination 5-azacytidine and nivolumab, Nivolumab
- Drug
- Lead sponsor
- Barbara Burtness
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Ruxolitinib, Dexamethasone
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Charlotte, North Carolina
- Conditions
- Neoplasms
- Interventions
- BI 1387446 50 μg, BI 754091, BI 1387446 100 μg, BI 1387446 200 μg, BI 1387446 400 μg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Milwaukee, Wisconsin
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Copanlisib, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Healthy
- Interventions
- Oxycodone hydrochloride tablet 30 mg, Roxicodone™ tablet 30 mg
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Letrozole
- Drug
- Lead sponsor
- Mridula George, MD
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Oral Budesonide, Elimination diet
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
- Interventions
- CB-5083, Dexamethasone
- Drug
- Lead sponsor
- Cleave Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Duarte, California • San Francisco, California • Atlanta, Georgia + 3 more
- Conditions
- HIV Infection
- Interventions
- HPV vaccine for strains -6, -11, -16, and -18
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 23 Years · Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
- Conditions
- Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Interventions
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 4 Years to 7 Years
- Enrollment
- 882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
- Conditions
- MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Romidepsin
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- Palbociclib Alone, Palbociclib plus itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Danirixin, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
- Conditions
- Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma
- Interventions
- FOLFIRINOX, Gemcitabine/nab-Paclitaxel, Radiation therapy, Capecitabine
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts